JAN 29, 2021 5:20 AM PST

Shorter radiation course effective for men with high-risk prostate cancer

Could shortening radiation courses for men undergoing treatment for prostate cancer be just as effective as conventional, longer courses? New research from the UCLA Jonsson Comprehensive Cancer Center suggests this just may be the case. Their findings are published in The International Journal of Radiation Oncology.

Men with high-risk prostate cancer typically undergo radiation courses that last 45 days. Such traditional courses require daily visits for treatment and can be burdensome for many men and their families, drastically altering the quality of life. Now new findings suggest that shortening radiation therapy from six-and-a-half weeks to five days of large-dose delivery may be a safe and effective alternative.

The shorter regimen consists of what is called stereotactic body radiotherapy (SBRT), which is a form of external beam radiation therapy that uses a higher dose of radiation than the 45-day course of radiotherapy. SBRT has been previously shown to be effective for men with low- and intermediate-risk prostate cancer, boasting a four-year cure rate of 82%.

In the study conducted, the researchers considered the efficacy and toxicity of SBRT in high-risk prostate cancer in seven institutional phase II trials and prospective registries. In their analysis, the team looked at data from 344 men with high-risk prostate cancer. The minimum follow-up was 24 months and the median follow-up was 49.5 months. They found that severe side effects from SBRT were rare, with approximately 2% of men experiencing urinary issues and less than 1% experiencing bowel side effects.
 

These data provide evidence that SBRT offers a safe and effective alternative treatment for men with high-risk prostate cancer. While the team cautions that more prospective studies are needed to evaluate the optimal dose and target volume, they say their findings represent a significant advancement that could improve the overall quality of life for patients.

Sources: The International Journal of Radiation Oncology, Eureka Alert

About the Author
BA Environmental Studies
Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 29, 2022
Health & Medicine
US-Funded Research to be Open Access by 2026 Under New Federal Guidance
AUG 29, 2022
US-Funded Research to be Open Access by 2026 Under New Federal Guidance
If you have ever done research for school or work, or simply been curious about a scientific finding and wanted to read ...
SEP 04, 2022
Drug Discovery & Development
Brief Exposure to Cancer Drug Produces Anti-aging Effects in Mice
SEP 04, 2022
Brief Exposure to Cancer Drug Produces Anti-aging Effects in Mice
Brief exposure to rapamycin, a promising anti-aging drug, may have similar effects on health and lifespan as longer trea ...
SEP 19, 2022
Genetics & Genomics
CGP: Simplifying the path from tumor to treatment
SEP 19, 2022
CGP: Simplifying the path from tumor to treatment
The promise of NGS in personalized cancer care For years, next-generation sequencing (NGS) has enabled oncologists to id ...
NOV 16, 2022
Drug Discovery & Development
Flavonoid Delivery Using Nanoparticles Currently On Route
NOV 16, 2022
Flavonoid Delivery Using Nanoparticles Currently On Route
In their article, Dewanjee et al. explains how the use of nanoparticles is a novel solution that can specifically addres ...
NOV 24, 2022
Cancer
Pass the Cranberries- They Just Might Help Prevent Cancer
NOV 24, 2022
Pass the Cranberries- They Just Might Help Prevent Cancer
Today across the United States, families gather to celebrate Thanksgiving, a day to give thanks for the previous year&rs ...
NOV 21, 2022
Cancer
More People Living with Metastatic Cancer
NOV 21, 2022
More People Living with Metastatic Cancer
Experts define metastatic cancer as cancer that spreads from the anatomical location where it started to a distant part ...
Loading Comments...